Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$100,000.00
Oct 1, 2014
The Effects of Psoriatic Arthritis on Coronary Flow Reserve and Markers of Inflammation and Evaluation of the Response to Biological Therapy
$1,349,755.00
Oct 1, 2014
Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial: Proposal of an International Registry and Randomized Controlled Trial (RCT)
$100,000.00
Oct 1, 2014
A pragmatic randomized controlled trial of group transdiagnostic cognitive-behaviour therapy for anxiety disorders in primary care
$100,000.00
Oct 1, 2014
The Coming Revolution in HCV Therapy: Will HIV-HCV co-infected patients really benefit?
$250,468.00
Oct 1, 2014
Cochlear gene therapy targeting the protection against aging related hearing loss and neuronal degeneration
$495,930.00
Oct 1, 2014
Exploiting synthetic lethality in Renal Cell Carcinoma: Targeting the loss of the von Hippel-Lindau tumor suppressor gene through autophagy for the development of anticancer therapy
$100,000.00
Oct 1, 2014
Gene Therapy for PAX6-Aniridia: Focusing on the Eye
$100,000.00
Oct 1, 2014
The role of NMNAT2, a new p53 target gene, in feedback regulation of p53 function via the SIRT deacetylases.
$654,884.00
Oct 1, 2014
Host-Mediated Control of Virulence and Immunity Genes in Vibrio cholerae
$366,920.00
Oct 1, 2014
Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial